We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Zoledronic acid (Reclast/Aclasta) — bisphosphonate
A once-yearly intravenous bisphosphonate for osteoporosis that drew geroscience attention because, in a major fracture trial, it reduced not just fractures but all-cause MORTALITY — a benefit larger than bone effects alone explain. Emerging work suggests immune-modulating and possibly senescence-related effects. The mortality signal is real but not fully understood; human longevity is unproven. A prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Zoledronate is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Zoledronate studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2026 with a typical study size of 211 participants.
Based on 101 studies · 17 meta-analyses · 76 RCTs · 64,110 total participants
Confidence
High confidenceBy outcome
Zoledronate has proven fracture-prevention benefit and a striking all-cause-mortality signal in a hip-fracture trial (HORIZON) larger than bone effects explain, with emerging immune/senescence hypotheses — but the mortality signal is inconsistently reproduced, the mechanism is unresolved, and there is no human lifespan/healthspan trial, so the geroprotector case is intriguing but unproven.
94 rigorous studies
76 randomized trials · 15 meta-analyses · 13 systematic reviews
Our evidence rating for Zoledronate is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
49 trials ongoing or recruiting · 245 completed on ClinicalTrials.gov
95 of the completed trials have posted results
Registered trials show research momentum for Zoledronate, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Zoledronic acid is a potent nitrogen-containing bisphosphonate given as a once-yearly intravenous infusion to treat and prevent osteoporosis (and, at higher doses, cancer bone disease).
Bisphosphonates bind exposed bone mineral and trigger apoptosis of bone-resorbing osteoclasts, reducing bone turnover and fracture risk.
Its geroscience interest arose from an unexpected clinical observation: in the HORIZON Recurrent Fracture Trial, yearly zoledronic acid after a hip fracture reduced new clinical fractures AND lowered all-cause mortality by about 28% — a survival benefit too large to be explained by fracture reduction alone, prompting hypotheses about pleiotropic effects.
Proposed mechanisms beyond bone include effects on the immune system (it activates gamma-delta T cells), on vascular calcification, and possibly on cellular senescence and the DNA-damage response — leading to interest in bisphosphonates as geroprotectors, summarized in 'bisphosphonates and lifespan' reviews.
The honest picture is that the mortality signal, while striking, has not been consistently reproduced across all bisphosphonate analyses, the mechanism is unresolved, and there is no trial testing zoledronate for lifespan/healthspan in people without osteoporosis.
It is generally safe but has characteristic issues: an acute flu-like 'acute-phase reaction' after the first infusion, hypocalcemia, kidney caution, and rare osteonecrosis of the jaw and atypical femur fractures with long-term use.
Zoledronate is a prescription drug used off-label for its proposed geroprotective effects; it is not a dietary supplement. The score reflects a real, intriguing mortality signal and proven bone/fracture benefit, against an unresolved mechanism and no human longevity trial.
Zoledronate binds bone mineral and triggers osteoclast apoptosis (via the mevalonate pathway), reducing bone resorption and fracture risk.
It activates gamma-delta T cells and alters macrophage/immune function — a proposed contributor to the non-skeletal mortality benefit.
Emerging work links bisphosphonates to effects on cellular senescence and the DNA-damage response — the basis of geroprotector interest, still unproven.
How Zoledronate works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid below CrCl 35; hydrate and monitor kidney function.
Address dental issues first — osteonecrosis-of-the-jaw risk.
Avoid — bisphosphonates persist in bone and are not used in pregnancy.
Additive kidney risk — ensure hydration and renal monitoring.
Additive hypocalcemia risk.
Tip: Fever/aches in the days after the first infusion; usually self-limited, less with later doses.
Tip: Correct vitamin D and calcium before dosing.
Tip: Rare with long-term use; dental check before therapy; consider drug holidays.
Zoledronate has an evidence score of 3/10 — emerging evidence based on 19 indexed studies. A once-yearly intravenous bisphosphonate for osteoporosis that drew geroscience attention because, in a major fracture trial, it reduced not just fractures but all-cause MORTALITY — a benefit larger than bone effects alone explain. Emerging work suggests immune-modulating and possibly senescence-related effects. The mortality signal is real but not fully understood; human longevity is unproven. A prescription drug, not a supplement. Representative study: PMID 17878149.
The commonly studied dose of Zoledronate is Approved osteoporosis dosing is a single 5 mg intravenous infusion once yearly, given by a clinician (with adequate calcium/vitamin D and hydration). There is no validated longevity regimen; off-label geroprotective use would follow the same infusion under medical supervision.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Zoledronate — consistent daily use matters more than the time of day. A once-yearly intravenous infusion given in a clinic; not a daily/oral regimen.
Zoledronate should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are acute-phase reaction (flu-like), hypocalcemia, osteonecrosis of the jaw / atypical femur fracture. Use caution if any of these apply to you: Hypocalcemia (uncorrected); Severe renal impairment (CrCl < 35); Pregnancy.
Beta-Sitosterol
Likely helpsPlant sterol that reduces BPH urinary symptoms in clinical trials and blocks intestinal cholesterol absorption.
Collagen
Likely helpsHydrolyzed peptides that rebuild skin elasticity, reduce joint pain, and strengthen bone density — results build over 8-12 weeks.
Quercetin
Likely helpsFlavonoid with senolytic and anti-inflammatory properties — supports immune defense, allergy relief, and exercise performance.
Soy Isoflavones
Likely helpsPlant compounds with weak estrogenic effects that support menopausal symptoms, bone health, and cardiovascular function.
Explore: Best supplements for Body Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 101 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research